TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) program: 5-year retrospective hepatic safety assessment
The tREMS Program effectively mitigates the risk of hepatotoxicity through careful monitoring and early intervention. Pexidartinib remains a viable treatment option for TGCT when managed according to recommended guidelines.
Authors
- Charles Dharmani (ORCID: https://orcid.org/0000-0003-3641-9738)
- Oluwatosin Fofah (ORCID: https://orcid.org/0000-0003-2470-8276)
- Margaret Wooddell (ORCID: https://orcid.org/0009-0008-3657-6614)
- Abdul Waheed Rajper (ORCID: https://orcid.org/0009-0000-6468-7380)
- Lalitha Chilakapati
Institutions
- Daiichi Sankyo (Germany) (DE)
- Daiichi-Sankyo (South Korea) (KR)
- Daiichi Sankyo (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1080/14796694.2025.2509409
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00